Molecular Targeting Technologies, Inc. and University of Antwerp Begin First-in-Human Study of TDURA Diagnostic for Early Detection of Response to Colon Cancer Therapy

Published: May 11, 2021
 
 
WEST CHESTER, Pa.--(BUSINESS WIRE)-- Molecular Targeting Technologies, Inc.   (MTTI) and University of Antwerp today announced the approval of a Clinical Trial Application by the European Federal Agency for Medicines and Health Products (FAMHP) (equivalent to a US IND). The clinical study will evaluate the safety, dosimetry and treatment response of TDURA (
99mTc-Duramycin), in patients with advanced colorectal cancer (CRC)*.
Colorectal cancer is the third most commonly diagnosed malignancy in the world and the second leading cause of cancer death in the United States. While a range of novel active agents has improved the prognosis of patients with colorectal cancer, 50% of advanced colorectal cancer patients die from metastatic disease.

Related Keywords

United States ,Sigrid Stroobants ,Chris Pak ,Molecular Targeting Technologies Inc ,European Federal Agency For Medicines ,Nuclear Medicine ,National Institutes Of Health ,University Of Antwerp ,Health Products ,Targeting Technologies ,Clinical Trial Application ,European Federal Agency ,National Institutes ,National Cancer Institute ,ஒன்றுபட்டது மாநிலங்களில் ,கிறிஸ் பக் ,அணு மருந்து ,தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் ,பல்கலைக்கழகம் ஆஃப் ஆண்ட்வெர்ப் ,ஆரோக்கியம் ப்ராடக்ட்ஸ் ,மருத்துவ சோதனை விண்ணப்பம் ,தேசிய நிறுவனங்கள் ,தேசிய புற்றுநோய் நிறுவனம் ,